Dana Yealy
Family · Hanover, PANPI 1346750395
Payments from drug & device makers
Across 242 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$800
- Lilly USA, LLC$514
- GSK$281
- AstraZeneca$199
- Pfizer$189
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$187
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,108100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $800 |
| Lilly USA, LLC | 28 | $514 |
| GSK | 20 | $281 |
| AstraZeneca | 12 | $199 |
| Pfizer | 12 | $189 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $187 |
| Boehringer Ingelheim | 11 | $171 |
| Novo Nordisk | 8 | $148 |
| Amgen | 7 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $127 |
| Teva Pharmaceuticals USA, Inc. | 6 | $120 |
| Radius Health, Inc. | 4 | $112 |
| Novartis | 7 | $107 |
| E.r. Squibb & Sons, L.L.C. | 5 | $102 |
| Merck | 6 | $97 |
| Exact Sciences | 4 | $92 |
| Bayer | 4 | $81 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 3 | $53 |
| Ironshore Pharmaceuticals Inc. | 3 | $50 |
| Abbott | 2 | $45 |
| Astellas Pharma US Inc | 2 | $42 |
| Johnson & Johnson | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $29 |
| Medtronic | 1 | $26 |
| Seqirus USA Inc | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $19 |
| Organon | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Neurelis, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
How this compares
$4,120 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $100,930 |
| TrulicityDulaglutide | 19 | $26,487 |
| JanuviaSitagliptin Phosphate | 16 | $25,642 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,211 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $18,877 |
| MounjaroTirzepatide | 16 | $16,147 |
| XareltoRivaroxaban | 13 | $13,619 |
| RybelsusSemaglutide | 13 | $11,063 |
| Repatha SureclickEvolocumab | 11 | $6,198 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $3,733 |
| Atorvastatin Calcium | 476 | $3,042 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $2,890 |
| Gabapentin | 167 | $2,808 |
| Doxazosin Mesylate | 136 | $2,619 |
| Metoprolol Succinate | 186 | $2,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $189 | $102,359111 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $514 | $43,50748 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $281 | $40,08853 claims |
| MerckJanuvia | $97 | $25,64216 claims |
| Johnson & JohnsonXarelto | $32 | $13,61913 claims |
| Novo NordiskRybelsus | $148 | $11,06313 claims |
| AbbVieSynthroid | $800 | $83734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Hanover
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.